

---

# Index

---

- accidents 7, 32
  - see also* traffic deaths
- ACE inhibitors 290
- Adam, Taghreed 46–61
- addiction 62
  - see also* drug use
- adolescence *see* young people
- adult day care 298
- advertising, direct to consumer 306–14
  - and agency relationships 309–10
  - care-seeking effect 309
  - and chronic illness 310
  - consumer reaction 310–11
  - historical background to 306–8
  - impact of 311–12
  - literature on 308–9, 310–12
  - and Medicaid spending 312–13
  - and Medicare 313
  - moral hazard 309
  - prescribing patterns 312
  - price elasticity 310
- Afghanistan
  - contracting-out 252, 256
  - public health intervention 55
- Africa
  - internet access 167
  - public health intervention 55, 58
- ageing 19, 20, 33
  - disability rate 297
  - and distributional judgements 383–4, 385
  - and health subsidies 115–16
  - mortality rate 297–8
  - and risk adjustment 279, 280, 282
  - see also* retirement
- AIDS 55, 251, 252, 479, 540
  - see also* HIV
- air quality 47
- Albania
  - GATS commitments 168
  - unofficial health care economy 156
- alcohol use 5, 11, 36
  - by young people 62, 64, 65, 66, 67, 68–9
  - cost-effective analysis 480–86, 488–9
  - legal drinking age 84
  - and traffic deaths 10
  - Zero Tolerance laws 68–9
- Alzheimer Disease 364
- ambulance services, and EuroWill project 396–7, 398
- amphetamines 85
- anthropometric records 48
- antibiotics 173, 540
- Antigua and Barbuda, GATS commitments 168
- antimicrobials 53
- antiretrovirals 54, 58
- Argentina
  - child mortality 50
  - unofficial health care economy 159
- Armenia, GATS commitments 168
- Arrow, K.J. 46, 97–8, 104, 131, 270, 394
- arthritis 114, 115, 118
- Asia, equity in health and health care systems 205–18
  - benefit incidence analysis 209–11
  - empirical analysis of 205–6
  - empirical evidence 206–14
  - Equitap study 206, 208, 209, 210, 211, 212
  - ETEN (equal treatment for equal need) 207
  - Europe, comparisons with 213–14
  - financing, vertical equity in 211–12, 214
  - future agenda 215–16
  - high income countries 207, 209
  - low- and middle-income countries 206–7, 208, 209, 211, 214, 215–16
  - poverty impact of health care expenditure 212–13, 216
  - private financing 214
  - rent-seeking 215
  - social security systems 214
  - tax systems, predominant 214–15
  - transition economies 215
  - see also* individual countries
- Asian Development Bank 254
- assisted living 298
- asthma 77, 120, 367
- Auld, M. Christopher 36–45, 68, 152, 154
- Australia
  - child mortality 50
  - cost-effective analysis 495, 498
  - drug insurance scheme, national 120
  - drug-related crime 83, 85
  - drugs price bargaining 237
  - GATS commitments 168

- health care use 150
- health services trade 170
- patient cost sharing 118–19
- pharmaceuticals evaluation 430, 498, 537, 541–2, 543
- providers, temporary movement of 171, 172
- Austria 23, 24
  - child mortality 49
  - GATS commitments 168
  - hospital competition 228
- back problems 10, 42
- bandwagon effect 62–3
- Bangladesh
  - child health and maternal services 209
  - child mortality 207
  - contracting-out 252, 254
  - government social spending 209
  - health care financing 212
  - health care utilization 208
  - health inequalities 206
  - poverty and health care expenditure 212, 213
  - providers, temporary movement of 171
  - tax and direct payments mixed systems 215
  - unofficial health care economy 156–7, 158
- Barbados, GATS commitments 168
- bargaining in health care *see* negotiation and bargaining in health care
- Barros, Pedro Pita 233–41
- Basu, Anirban 154, 430, 442, 455–65
- Bayesian decision theory 110, 515, 516–17, 531, 540
- behaviour, causal effects of health-related 36–45
  - heterogeneous effects 40–43
  - instrumental variables estimation 36–40
- behaviour, health, and young people 62–71
- Belgium
  - health insurance 112
  - hospital competition 228
  - Panel Study 23, 24
- Belize, GATS commitments 168
- Bernouli, Daniel 96
- Birch, Stephen 471, 477, 484, 492–502
- Bishai, David 46–61
- Bismark health care systems 223, 228
- Bleichrodt, Han 347–58, 373, 386, 388, 393, 405
- BMI (body mass index) 66, 72–3, 75, 78
- Bolivia
  - GATS commitments 168
  - unofficial health care economy 159
- Boots Pharmaceuticals 307
- Botswana, GATS commitments 168
- Bound, J. 26, 28, 31, 32, 33, 39
- Box-Cox models 440–41, 442–3
- Bradford, W. David 306–14, 339
- 'brain drain' 171–2
- Brazier, John 348, 360, 361, 365, 371–81, 388, 405
- breast cancer 77, 455–6
  - QALY outcome 456, 463–4
- Breyer, Friedrich 126–36
- Briggs, Andrew 480, 488, 503–13, 515, 528
- Brunei Darussalam, GATS commitments 168
- Bulgaria
  - GATS commitments 168
  - unofficial health care economy 156
- Burgess, James F., Jr 320, 335–42
- Burgess, Leonie 386, 405, 406, 408, 415–26
- Burkina Faso, public health intervention 55
- Burundi, GATS commitments 167, 168
- Cambodia
  - contracting-out 252, 254, 256
  - unofficial health care economy 156, 162
- Canada
  - ageing in 31
  - bargaining in health care 237
  - child mortality 50
  - cost-effective analysis 495, 498–9, 537
  - DCA (direct to consumer advertising) 306, 313
  - drug plans for seniors 116
  - drug-related crime 83, 85
  - GATS commitments 167
  - inequalities in self-reported health 181
  - NPHS (National Population Health Survey) 29
  - OHIP (Ontario Health Insurance Plan) 29
  - patient cost sharing 118–19
  - payment rates 265
  - Pharmacare 118, 119, 120
  - pharmaceuticals evaluation 116, 495, 498–9, 537, 541–2
  - providers, temporary movement of 171, 172
  - public drug plan 119–20
  - quality assessment 362–3, 366
  - SLID (Survey of Labour and Income Dynamics) 20
  - taxing health benefits 114–15
  - USA, importing drugs from 114, 121
- cancer 7, 8, 9, 77, 78, 447, 452, 486
  - and EuroWill project 398
  - and QALY model 349
  - screening 290
  - see also* breast cancer; cervical cancer

- capitation system  
 contracts, information and incentives in  
 health care 263, 264, 265–7  
 and decision-making 273  
 future research 275–6  
 and GPs 269–78  
 health services quality and quantity, effects  
 on 272–3  
 and hospitalization 271, 274  
 and mental health 290  
 need-based 274–6  
 and primary care incentives 269–78  
 referral rate 273–4  
 revenue system component 274–5  
 risk adjustment *see* risk adjustment
- cardiovascular disease 469, 477  
 and advertising 310  
 cost-effective analysis 483  
 and economic instability 5, 7, 8, 9  
 EPIC drug 542
- care homes *see* nursing home quality of care
- Caribbean, providers, temporary movement of  
 171
- cataract operations, and EuroWill project 398
- cereal breeding programmes 52
- cervical cancer 469
- Chalkley, Martin 224, 234, 242–9, 250, 275,  
 323
- children  
 in developing countries, public health  
 interventions 46–61  
 mortality 5, 8–10, 46, 48–51, 53–5, 58, 159,  
 205, 206–7, 251, 254  
 nutrition, effective 48–51, 486  
*see also* poverty; young people
- Chile  
 child mortality 50  
 health services trade 170
- China  
 cross-border supply of services 167  
 GATS commitments 168  
 health care financing 212, 215  
 health care utilization 208  
 legal drinking age 84  
 poverty and health care expenditure 212, 213  
 smoking 65  
 unofficial health care economy 156
- Chinese Taipei, GATS commitments 168
- Chisholm, Dan 479–91
- cholera 54
- cholesterol levels 540–41
- chronic illness 18, 29, 32, 114, 115, 289, 540  
 and advertising 310  
 health utility measurement 347–52
- Claxton, Karl 480, 488, 514–25, 542
- cocaine 64, 84, 85
- Colombia, unofficial health care economy 159,  
 160
- colon cancer 78
- Columbia, child mortality 50
- communicable diseases 48
- community care, and EuroWill project 398
- community support, loss of 12
- CON (certificate of need) policies 298, 300,  
 301, 302
- Congo RP, GATS commitments 168
- consumer behaviour, neoclassical model of 62
- Contoyannis, Paul 17–25, 119, 190
- contracting-out health service provision  
 250–58  
 accountability 257  
 contract evaluation 253  
 examples of recent 254–6  
 external funding 256  
 future research 257  
 and globalization 257  
 government subsidies 251  
 impact on health system 257  
 international funding agencies 250  
 motivation for 251–2  
 New Public Management 251  
 performance-based 256  
 policy implications 256–7  
 resource allocation 251–2, 254, 255, 256–7  
 in resource- and information-poor settings  
 250–58  
 services suitable for 252, 255
- contracts, information and incentives in health  
 care 242–9  
 capitation system *see* capitation system  
 costs of health care 245–6  
 dumping 245–6  
 fee-for-service systems 263, 264, 266, 270,  
 271, 272, 275, 286, 290  
 fixed prices, policy implications of 246–8  
 hidden information 243, 244–6, 250, 256  
 moral hazard 243–6, 323  
 rent-seeking behaviour 248  
 salary system 263–4, 270  
 services, defining 247–8, 250
- Cookson, Richard 24, 194, 221–32, 247, 385
- cooperatives 254–5
- Copas' tests 444
- cost-effectiveness acceptability curve (CEAC),  
 and decision-making 515–16
- cost-effectiveness analysis and clinical trials,  
 statistical methods 503–13  
 applications 508–10

- extensions 508–10
- Heart Protection Study 509–10, 511
- ICER statistic 504, 505, 507
- net-benefit regression 506–7, 508
- net-benefit statistic 504–5
- QALY 509
- standard approach to stochastic 503–6
- cost-effectiveness analysis, decision rules for
  - incremental 469–78
  - ‘competing choice’ problem 473–5
  - framework extensions 476–8
  - health improvement, maximising 471–2, 475
  - HIV example 469, 470–71, 475, 476–7
  - indivisibilities 476–7
  - interdependence between programmes 476
  - multiple resource constraints 478
  - programme alternatives 473–5
  - QALY 471–2, 473–5, 495
  - ‘shopping spree’ problem 471–2, 475
- cost-effectiveness analysis, future costs in
  - 447–54
  - empirical studies 449–53
  - ethical and policy concerns 453
  - historical background 447
  - and life expectancy 453
  - lifetime decision-making models 448–9
  - methods 451–2
  - QALY 447, 451, 452
  - theoretical background 447–9
- cost-effectiveness analysis, generalized,
  - principles and practice 479–91
  - alcohol use 480–86, 488–9
  - challenges 479–80
  - IMC-CEA (intervention-mix constrained) 479
  - policy uses 489–90
  - practice of 486–8
  - principles of 480–86
  - QALYs 480, 487, 488, 489, 497, 499
  - risk factors 488–9
  - sectoral analysis 479
- cost-effectiveness thresholds, and decision-making 543–4
- cost-utility analysis *see* health utility measurement
- Costa Rica
  - child mortality 51
  - contracting-out 254–5, 256
  - cooperatives in 254–5
  - GATS commitments 168
  - Social Security Fund 255
- costs for economic evaluation, estimating
  - 429–38
  - censoring 432–5
  - cost analysis 430–35
  - cost collection 429–30
  - generalised equations 435
  - missing data 431–2, 435
  - skewed costs 430–31
- costs and expenditures, skewed data on
  - 439–46
  - alternative estimation approaches 440–43
  - Box-Cox models 440–41, 442–3
  - generalised linear model (GLM) 441–3, 444
  - OLS model 439, 441, 442, 444
  - retransformation problem 441
  - strengths and weaknesses 443–4
- crime and illicit drug use 83–92
- Croatia
  - capitation system for GPs 271
  - GATS commitments 168
- crop breeding programmes 52
- Cuba, health services trade 170
- Currie, Gillian 247, 386, 405–14
- Cutler, D.M. 48, 52, 76, 77, 80, 105, 110, 142, 238, 280, 283, 297, 301
- Cyprus, hospital competition 228
- cystic fibrosis screening 404
- Czech Republic
  - GATS commitments 168
  - health plan competition 221
- Dawson, Diane 221–32, 247
- DCA (direct to consumer advertising) *see* advertising
- Deb, Partha 147–55
- decision rules in economic evaluation 492–502
  - alternative approach 499–500
  - and cost-effective analysis 492–3, 494–500
  - economic basis 492–4
  - needs of decision-makers 495–8
- decision-making
  - CEAC (cost-effectiveness acceptability curve) 515–16
  - central level 537–8
  - clinical studies 539–41
  - cost-effectiveness thresholds 543–4
  - economic evaluation and 537–45
  - evidence acquisition 517–23
  - EVPI (expected value of perfect information) 517–23
  - local level 538–9
  - methodological issues 539–41
  - QALY 541, 543–4
  - requirements of 514–15
  - technology adoption 515–17
  - with uncertainty 514–25
- Dengue fever 54

- Denmark  
 capitation system for GPs 271  
 child mortality 49  
 EuroWill project 398  
 hospital competition 228  
 Panel Study 23, 24  
 physician payments 266  
 public health expenditure 221  
 willingness to pay 398, 399
- dental care 132
- depression 115, 289  
 Robert Wood Johnson Foundation 289
- developing countries  
 child mortality 46  
 e-health 169  
 FDI 170–71  
 health care workers, shortage of 52–3, 58  
 and health services trade 170  
 public health interventions for children in  
 46–61  
 water quality 52  
*see also* individual countries
- diabetes 120, 283, 289, 290, 309, 450, 452, 540  
 type 2 77, 78
- dialysis 364, 452
- diarrhoea 52, 183, 209
- diet 10, 12, 18, 73, 452  
 calorie consumption 73–4  
 food as addiction 76  
 food price 52, 66, 75–6, 77, 79  
*see also* nutrition; obesity
- digestive system 200
- disability insurance 26, 29, 31, 32, 33
- Discrete Choice Experiment 386
- Dolan, Paul 129, 352, 355, 361, 373–4, 376,  
 382–91, 384, 385, 387, 541
- Dominican Republic, GATS commitments 168
- Donaldson, Cam 247, 270, 372, 392–402, 405,  
 411, 497, 499, 544
- donor agencies 52
- Dowd, Bryan 99, 111, 137–46, 221, 247
- DPT vaccine 54
- Dranove, D. 39, 224, 226, 265, 331, 429, 430
- DRGs (Diagnosis Related Groups) 224, 225,  
 228, 229
- drug use 36, 40, 62–6, 67, 68  
 amphetamines 85  
 background on illicit 83–4  
 cocaine 64, 84, 85  
 crime and illicit drug use 83–92  
 decriminalization 87, 88–9  
 demand and supply 86–8  
 dependency 84  
 and employment 84  
 future research challenges 89–90  
 harm-reduction 88–9  
 heroin 84, 87  
 inhalant drugs 84  
 legalities of 83, 84  
 legalization 87, 88–9  
 ‘lifestyle’ drugs 118  
 marijuana 66, 67, 83, 84, 88  
 needle exchange 88–9  
 PA (prior authorization) for prescription  
 drugs 118  
 patient cost sharing 118–20  
 prescription drug insurance, moral hazard  
 116–21  
 prescription drug insurance and  
 reimbursement 114–25  
 prescription drug price discounts 120–21  
 preventive programmes 87–8  
 and sexual behaviour 40  
 smuggling 88  
 treatment for 85, 87  
*see also* individual countries
- Drummond, Michael 56, 359, 365, 371, 430,  
 479, 500, 505, 537–45
- dual practice 157
- dynamics of health 17–25, 30, 33  
 empirical analysis of 19–21
- dyslipidemia 77
- ear complaints 200
- Eastern Europe  
 providers, temporary movement of 171  
*see also* individual countries
- ECHP (Economic Community Panel) 21
- ECHP-UDB (*European Community Household  
 Panel User Database*) 23
- economic evaluation, distributional  
 judgements in 382–91  
 ability to pay 383  
 Discrete Choice Experiment 386  
 efficiency counter-argument 383  
 health variance 385–6  
 horizontal equity 384, 386  
 QALY, equality of 382–90  
 QALY, maximization, weighted 388–90  
 QALY, value of 386–8, 393, 394, 397–9  
 social perspective 386–7  
 vertical equity 383–4, 385  
*see also* preference-based measures for  
 health; quality of life assessment, health-  
 related
- economic growth  
 and child mortality 51  
 and health decline 11–12

- Ecuador, GATS commitments 168  
 education levels 17, 18, 19, 199, 202, 203  
 education and training 167, 170  
 emphysema 534  
 employment  
     and health insurance 108  
     and health service utilization 202, 203  
     and illicit drug use 84  
     injury risk at work 11  
     labour supply 30, 31, 32, 33  
     sedentary 75  
     working hours 11  
     *see also* health, and work; workforce  
 endocrine and metabolic disorders 200  
 endometrial cancer 78  
 England  
     equity in health care consumption 199–203  
     *see also* UK  
 Ensor, Tim 156–63, 215  
 environment, physical 7, 18, 46, 47  
 epidemiologic surveillance 47  
 epilepsy 540  
 Equitap study 206, 208, 209, 210, 211, 212  
 equity in consumption of health care  
     economic studies of 193–204  
     in England 199–203  
     horizontal and vertical inequity, recognising  
         198–9  
     inequity, problems in analyses of 196–9  
     welfare maximization and need 193–6  
 equity in health and health care systems, Asia  
     *see* Asia  
 Estonia  
     capitation system for GPs 271  
     GATS commitments 168  
 Ettner, Susan L. 266, 276, 286–95  
 EU  
     DCA (direct to consumer advertising) 306,  
         313  
     Equitap study 206  
     GATS commitments 168  
     health insurance and international  
         purchasing 134  
     macroeconomic effects on mortality 7, 8  
 Europe  
     Asia, comparisons with, equity in health and  
         health care systems 213–14  
     Bismark health care systems 223, 228  
     child mortality 46  
     comparisons with, Asia, equity in health and  
         health care systems 213–14  
     dual practice 157  
     GP and specialist use 208  
     health care financing 211  
     health insurance 147  
     health plans 138  
     incentive reimbursement 266  
     inequalities in self-reported health 181, 183  
     retirement 27  
     *see also* individual countries  
 EuroQol EQ-5D measure 361–2, 364, 365, 366,  
     372, 373, 377  
 EuroWill project 396–7, 398  
 Evans, David B. 479–91  
 exercise 10, 12, 36, 73, 75, 79, 452  
     physical inactivity 10, 11  
     *see also* diet; obesity; weight  
 eye complaints 200, 308–9, 373  
  
 family planning 52, 53  
 fee-for-service systems 263, 264, 266, 270, 271,  
     272, 275, 286, 290  
 Feeny, David 359–70, 371, 372, 375, 388, 405  
 Feldman, Roger 99, 111, 137–46, 221, 247  
 Fenwick, Elisabeth 480, 488, 514–25, 531, 542  
 Fieller's theorem 504  
 finite-sample properties, literature on 38–9,  
     40  
 Finland  
     child mortality 49  
     GATS commitments 168  
     hospital competition 221  
     obesity 10  
     Panel Study 23, 24  
 food pricing policies 52, 66, 75–6, 77, 79  
 foreign travel 170, 173  
     *see also* migration  
 France  
     child mortality 49  
     drug prescription 118  
     EuroWill project 398  
     hospital competition 228, 229  
     legal drinking age 84  
     Panel Study 23, 24  
  
 Gafni, Amiram 262, 393, 397, 471, 477, 486,  
     492–502, 544  
 gallbladder disease 77, 78  
 Gambia  
     child mortality 58  
     GATS commitments 167, 168  
     public health intervention 54, 58  
 Gamma model 444  
 GATS (General Agreement in Trade in  
     Services) 165–7, 168, 171, 172, 173  
 generic products 307  
 genitourinary system 200  
 genomics 173

- Geoffard, Pierre-Yves 58, 104–13, 116, 131, 280
- Georgia, GATS commitments 168
- Gerard, Karen 247, 270, 386, 393, 405–14
- Gerdtham, U.-G. 5, 6, 7, 9, 10, 11, 119, 128, 149, 154, 181
- Germany  
 child mortality 49  
 health plans 145, 285  
 hospital competition 228, 229  
 income levels 11, 19  
 macroeconomic effects on mortality 7, 8, 10, 11  
 outpatient visits 149  
 Panel Study 23, 24  
 pharmaceutical expenditure 271  
 social health insurance 128, 130  
 Socioeconomic Panel (GSOEP) 19  
 unemployment 32
- Gertler, P.J. 299, 300, 301, 337, 338
- GHQ (General Health Questionnaire) 23, 199
- Gini indices 22, 187
- Glazer, Jacob 112, 132, 235, 275, 279–85
- globalization  
 consumption abroad 169–70  
 and contracting-out health service provision 257  
 cross-border supply of services 167–9  
 e-health 167, 169  
 education and training, web-based 167  
 FDI (foreign direct investment) 170–71  
 future prospects 172–3  
 GATS 165–7, 171, 172, 173  
 and health economics 173–4  
 health governance, global 172  
 providers, temporary movement of 171–2  
 and trade in health services 164–75  
 and waiting lists 173
- Gold, M. 102, 374, 429, 430, 447, 493
- gonorrhoea 69
- government policies 46, 47, 64–5  
 and hospital competition 228–9  
 subsidies 251  
*see also* individual countries
- GP (general practitioner) fundholding (UK) 117–18, 119, 227, 238, 271, 274
- Grabowski, David C. 266, 296–305
- Gravelle, Hugh 5, 181, 193–204, 227, 272, 274, 275
- Greece 23, 24
- Grootendorst, Paul 40, 114–25, 365
- Grossman, Michael 11, 12, 17–18, 20, 27, 46–7, 62, 63–4, 66, 79
- Guyana, GATS commitments 168
- haemophilus influenza B 58
- Haiti, contracting-out 256
- hallucinogens 84
- Handbook of Health Economics* 296
- Harvard death spiral 110
- hay fever 307
- health  
 demand for 17–18  
 inequality 21–2  
 limitations 23–4  
 persistence in 18–19  
 predisposition to poor 18  
 and work, empirical models for 30–32  
 and work, literature on 28–33  
 and work, model for 26–8  
 and work, structural models for 32–3
- health capital model 11
- health care, contingent valuation in 392–404  
 ability to pay 394  
 clinical dilemmas 394–6  
 decision maker's dilemmas 394–9  
 health dilemmas 396–7  
 national dilemmas 397–9  
 WTP (willingness to pay) 392–9
- health care, contracts, information and  
 incentives in *see* contracts, information  
 and incentives in health care
- health care economy, unofficial  
 additional services enhancements 158  
 and child mortality 159  
 consumer choice of quality 161  
 contracting approaches 160–61  
 corruption approaches to 159–60, 161, 162  
 drugs payments 156  
 dual practice 157, 160–61, 162  
 'inxit' theory 158  
 in low- and middle-income countries 156–63  
 modelling 159–61  
 policy implications 161–2  
 'Robin Hood' effect 158  
 and wage levels 160, 161  
 willingness to pay 158
- health care, equity in consumption of *see*  
 equity in consumption of health care
- health care evaluation, perspectives on mean-based 526–36  
 CEAC (cost-effectiveness acceptability curves) 533–4  
 CER (cost-effectiveness ratios, incremental) 533–4  
 current criteria 533–5  
 decision-making 526–33  
 monetary benefit measures (NHBs) 533–4  
 net health benefit measures (NHBs) 533–4

- quantile treatment effects 534–5
- risk factors 527–33
- welfare assessment 534
- health care, inequalities in *see* inequalities in health care
- health care, negotiation and bargaining in
  - health care *see* negotiation and bargaining in health care
- health care organizations, performance
  - measurement *see* performance of health care organizations
- health care professionals, motivation of 248–9
- health care, publicly funded, hospital
  - competition and patient choice *see* hospital competition and patient choice
- health care systems, use of performance
  - measures in *see* performance measures in health care systems
- health care use
  - empirical models of 147–55
  - endogenous covariates 151–3
  - equity in 207–9
  - exogenous covariates 148–51
  - hurdle or two-part models 148–9, 150, 151
  - latent class models 150–51
  - parameters 153–4
  - Poisson regression model 148, 149, 150, 442, 444
  - zero-inflated models 149–50
- health economics, choice experiment design
  - 415–26
  - binary response experiments 419
  - choice models 417–19
  - discrete choice experiments 415–21
  - generic choice experiments 419–23
  - random utility theory 417–19
  - resolution 3 design 419
  - Scale Decomposition Model 425
  - understanding choice behaviour 416–17
  - unresolved issues 424–5
- health economics, discrete choice experiments
  - in 405–21
  - attribute identification 406–7
  - choice sets construction 407–8
  - concept of 406
  - data analysis 408–10
  - feasibility of 417
  - price as an attribute 407
  - QALY model 405, 410, 411
  - stages of 406–10
  - survey design 408
  - time as an attribute 407
  - validity of 411–12
  - willingness to pay 406, 410
- health insurance 26, 27, 29, 79
  - adverse selection 115–16, 126, 147
  - certainty, demand for 96–8, 105, 111
  - demand, price elasticity 108, 109
  - and e-health 169
  - employment linked 108
  - and FDI 170
  - and financial liberalisation 165
  - first best 105–6
  - health plans *see* health plans
  - incentive and selection effects in 104–13
  - income transfers, demand for 100–102, 105
  - ‘industrial purchasing’ 144
  - managed competition 144
  - market, and health plans 144–5
  - moral hazard 95, 98–9, 100, 101, 102, 104, 105–7, 108, 116–21
  - and mortality 111
  - physician as patient’s agent *see* physician as patient’s agent
  - pre-payment schemes 117–18
  - prescription drug 114–25
  - private, characteristics of 126–7, 137
  - RAND Health Insurance Experiment (HIE) 99, 109–10, 131, 151, 286, 440
  - reference pricing schemes 119, 120
  - regulation of 108
  - reimbursement 106–7
  - risk prediction 115–16, 126, 127, 142
  - second best 106–8
  - social *see* social health insurance
  - solidarity in 127–8
  - taxation, optimal 126–7
  - technological change in medicine 134
  - tiered cost sharing 119
  - USA *see* USA
  - utility concept 96, 97, 98, 101, 105
  - value of 95–103
  - welfare gain 100, 101, 102, 114, 142
  - welfare loss 98–9, 100, 101, 104–5, 121
- health plans
  - basic choice model, variations on 141–3, 152
  - choice literature 137–8, 142
  - competition and choice 137–46, 147, 221, 247
  - consumer characteristics 142
  - and health insurance market 144–5
  - individual level data 138–40
  - and market for health care services 143–4
  - market share data 140–41, 142
  - mental health patients 286–7
  - mergers 138
  - physician loyalty 137
  - plan switching 142–3



- profit maximization 283–4
- quality choices 282–4, 288, 330
- and risk adjustment *see* risk adjustment
- risk segmentation 142
- service-level selection 282–3
- study methods 138–41
- value-based purchasing 288
- health services trade and globalization *see* globalization
- health utility measurement 347–58
  - characterizations under expected utility 348–9, 353–4
  - chronic health states 347–52
  - generic utility model 351
  - life duration trade off 351–2
  - non-chronic health states 352–5
  - non-expected characterizations 350, 351, 355
  - prospect theory 351
  - QALY (quality-adjusted life-year) model 347, 348–50, 351, 353–4, 355–6, 366, 367, 371, 372
  - zero condition 348–9, 350
- health-related behaviour, causal effects of *see* behaviour
- heart disease 7, 8, 9, 10, 77, 120, 200, 289, 447, 450
  - and EuroWill project 398
  - myocardial infarction 7, 226
  - and performance monitoring 330, 331–2
  - risk reduction 392
  - treatment decision rules 493
- Heart Protection Study 509–10, 511
- Heckman, J.J. 41, 42, 108, 457, 462, 526, 533, 535
- helicopter ambulance 396–7, 398
- Hepatitis B 54
- Herfindahl-Hirschman Index of concentration 226
- heroin 84, 87
- Hicks, J.R. 52, 338, 395
  - see also* Kaldor-Hicks theory
- hip
  - fracture prevention 452
  - operations, and EuroWill project 398
  - treatment decision rules for 493
- HIV 58, 251, 252, 452, 469, 470–71, 475, 476–7, 479, 540
  - QALY 470
- Holland *see* Netherlands
- home health care 298
- homicide 62
  - and economic instability 5, 7–10
- Hong Kong
  - government social spending 209, 211
  - health care financing 211, 212, 214
  - health care use 207
  - health care utilization 208
  - poverty and health care expenditure 213
  - tax systems, predominant 214–15
- hormone replacement therapy 452
- hospice care 298
- hospital competition and patient choice 221–32
  - Bismark health care systems 223, 228
  - corporatism 228, 229
  - cross-border patient movement 228
  - DRGs (Diagnosis Related Groups) 224, 225, 228, 229
  - economic theory of 222–6
  - economies of scale 224
  - emergency services 224
  - entry and exit regulations 224, 225
  - fixed price regulation and non-price competition 225
  - geographical equity of access 226
  - imperfect, with no price regulation 224–5
  - 'league table' competition 223
  - 'medical arms race' 223
  - monopolistic 224–5
  - political constraints 228–9
  - price regulation 223–4
  - public funding limits 224, 225, 228–9
  - in publicly funded systems, evidence on 226–8
  - quality and waiting times 225, 227, 238
  - regulatory environment 223–4
  - reimbursement 223, 228
  - rent-seeking 228, 229
  - 'selective contracting' 224
  - supply-side impediments 223, 224
  - worker satisfaction 229
- hospitals, productivity measurement 336, 337
- HUI (Health Utilities Index) 361, 362, 363–4, 365, 366, 372, 373
- Hungary
  - GATS commitments 168
  - unofficial health care economy 156, 158
- hygiene 48–51, 486
- hyperlipidemia 115
- hypertension 77–8, 115, 118, 119, 120, 447, 452, 477, 486
  - willingness to pay 403
- IMCI (Integrated Management of Childhood Illness) 53
- immunization 53, 54, 55, 57–8, 254
  - and performance-based bonuses 290
  - see also* vaccination

- incentives in health care *see* contracts,  
information and incentives in health care
- income levels 6, 10–11, 17, 18–19, 20, 21–3,  
28  
and distributional judgements 383, 384  
and health service utilization 202, 203  
income mobility 21–4  
and weight 75
- India  
child health and maternal services 209  
child mortality 51, 207  
contracting-out 252  
e-health 169  
FDI 170  
GATS commitments 168  
government social spending 209, 211  
health care financing 212, 214  
health inequalities 206  
health services trade 170  
poverty and health care expenditure 213  
providers, temporary movement of 171  
tax and direct payments mixed systems 215
- Indonesia  
child health and maternal services 209  
child mortality 51, 207  
government social spending 209  
health care financing 212, 214  
health care utilization 208  
poverty and health care expenditure 212, 213  
tax and direct payments mixed systems 215
- inequalities in health care  
concentration index via linear regression  
179–83  
decomposition of 179–92  
difference in means 183–6  
distribution changes 186–90  
Oaxaca-type decomposition 179, 180–81,  
182, 183, 184, 187
- infants *see* children
- infectious diseases 199, 200
- infertility services 410
- influenza 7, 8, 9, 58, 452  
OTA study 447
- insecticide treated nets 53, 55
- international funding agencies 250
- 'inxit' theory 158
- Ireland  
EuroWill project 398  
Panel Study 23, 24
- Islamic societies, child mortality 51
- Israel, health plans 221, 285
- Italy  
child mortality 49  
hospital competition 221  
Panel Study 23, 24  
prescribing behaviour 309
- Iversen, Tor 117, 265, 266, 269–78
- Jamaica, GATS commitments 168
- Japan  
child mortality 50  
equity in health care 205  
GATS commitments 167, 168  
health care financing 211, 212, 214  
health care use 207  
social security systems 214
- JCAHO (Joint Commission on Accreditation  
of Health Care Organizations) 288, 290,  
292
- Johannesson, M. 5, 6, 119, 350, 355, 393, 394,  
397, 399, 430, 450, 495, 541
- Jones, Andrew M. 17–25, 65, 108, 190, 198,  
444
- Jordan, GATS commitments 168
- Kakwani indices 158
- Kaldor-Hicks theory 395, 526, 527, 529–31,  
534
- Kazakhstan, unofficial health care economy  
158, 161
- Kenkel, Don 62–71, 154, 312
- Kleit, Andrew N. 306–14
- Korea  
health care financing 211, 214  
health care use 207  
poverty and health care expenditure 213  
social security systems 214
- Kuwait  
child mortality 51  
GATS commitments 168  
health care quality 170
- Kyrgyzstan  
GATS commitments 168  
government social spending 209  
health care financing 212, 214  
social security systems 214  
unofficial health care economy 156, 161–2
- labour supply 30, 31, 32, 33  
*see also* employment
- Lagrange multiplier 195
- Lakdawalla, Darius 64, 72–82, 297–8
- Latin America  
unofficial health care economy 156, 159, 161  
*see also* individual countries
- Latvia, GATS commitments 168
- league tables, mortality 329
- Leapfrog Group for Patient Safety 288

- leisure time 12, 27, 32–3
- Lesotho  
contracting-out 252  
GATS commitments 168
- Lindeboom, Maarten 19, 21, 26–35
- Lithuania, GATS commitments 168
- liver disease 7, 8, 9
- location-specific fixed effects, and pooled data 6–11
- Louvière, Jordan 143, 386, 405, 406, 415–26
- Lurås, Hilde 117, 265, 266, 269–78
- Luxembourg  
hospital competition 228  
Panel Study 23, 24
- Macao, cross-border supply of services 167
- Macedonia, GATS commitments 168
- McFadden, D. 138, 377, 406, 408, 417, 418, 424
- McGuire, Ali 247, 429–38
- McGuire, Thomas G. 112, 132, 235, 242, 270, 275, 279–85, 323
- macroeconomic conditions  
and health and mortality 5–12  
location-specific fixed effects 6–11
- Madagascar, contracting-out 252
- malaria 47, 52, 54, 55, 251, 479, 486
- Malawi  
contracting-out 252  
GATS commitments 168
- Malaysia  
equity in health care 205  
FDI 170  
GATS commitments 168  
government social spending 209, 211  
health care utilization 208  
tax systems, predominant 214–15
- mammography, and performance measurement 332
- Manning, Willard 99, 102, 109, 128, 131, 149, 247, 430, 431, 439–46, 504, 508
- marijuana 66, 67, 83, 84, 88
- Martinez-Giralt, Xavier 233–41
- Mason, Helen 247, 392–402, 405
- measles 48, 54, 57
- Medicaid 95, 101, 118, 537  
and advertising, direct to consumer 312–13  
drug programme 120–21  
financial incentives 288–9  
mean-based evaluation 527  
nursing home quality of care 296, 297, 298, 299, 300–301, 302  
and obesity 78, 79  
payment system 246  
prescription reimbursement 119  
report card 330  
risk adjustment 284
- medical care, and health insurance *see* health insurance
- medical research 173
- Medicare 95, 137, 223, 287, 455–6, 463  
and advertising, direct to consumer 313  
financial incentives 288–9  
hospital care 117, 226, 248  
nursing home quality of care 296, 297, 298, 299, 301–2  
and obesity 78, 79  
open enrolment 246, 248, 265, 281, 282  
payment system 142, 225, 246, 248, 265  
risk adjustment 284–5, 440
- Medline 167
- Meltzer, David 399, 447–54, 488
- meningitis 54
- mental health 200, 486  
and economic instability 5, 10, 11, 12  
financial incentives 288–93  
and illicit drug use 84  
incentives in improving care quality 286–95  
inequalities in 19, 23  
patients' abilities, undermining 286  
pay-for-performance programmes 288, 289–90  
psychosocial health 199  
quality measures, evaluation of 290–93  
risk adjustment 292  
value-based purchasing 288
- methadone maintenance 87
- Mexico  
child mortality 50  
GATS commitments 168  
and health services trade 170
- migration 12, 170, 171, 172  
*see also* tourism
- Mills, Anne 55, 212, 250–58
- Miyamoto, J.M. 348–9, 350, 351, 352
- mobility indices 21–4
- Moldova, GATS commitments 168
- Mongolia, social security systems 214
- Monte Carlo model 40, 56, 515, 540
- Mooney, G. 197, 262, 266, 270, 271, 392, 393
- morphine 84
- Morris, Stephen 193–204
- mortality  
adult 7–10, 297–8  
child 5, 8–10, 46, 48–51, 53–5, 58, 159, 205–7, 251, 254  
decline, and public health intervention 48–51  
elderly 297–8

- and health care inequity 196–9
- and health insurance 111
- and hospital competition 226–7
- league tables 329
- and macroeconomic conditions 5–12
- and performance measurement 323, 329, 330–31
- reduction, and vitamin A supplementation 48, 55, 57, 58
- Mozambique, public health intervention 54
- Mullahy, John 152, 154, 430, 441, 442, 444, 504, 514, 515, 526–36
- musculoskeletal system 199, 200
- negotiation and bargaining in health care 233–41
  - ‘any willing provider’ approach 235, 236, 239
  - future research 239
  - group preferences 237
  - models of 234–7
  - Nash bargaining solution 234–5, 237
  - outcomes evidence 237–8
  - pharmaceutical product financing 237, 239
  - public-private partnerships 236–7, 239
  - third-party payer decisions 235–6, 237, 238, 239
  - timing of 239
- neonatal deaths, and economic instability 8
- neoplasms and benign growths 200
- Nepal
  - child health and maternal services 209
  - child mortality 51, 58, 207
  - FDI 170
  - health care financing 212, 214
  - health care utilization 208
  - health care workers, shortage of 53
  - health inequalities 206
  - poverty and health care expenditure 213
  - public health intervention 55, 58
  - tax and direct payments mixed systems 215
  - unofficial health care economy 156
  - vitamin A programme 58
- nervous system 200
- Netherlands
  - capitation system for GPs 271
  - health expenditure 129
  - health plan competition 221
  - health plans 145, 285
  - hospital competition 228
  - marijuana use 83
  - Panel Study 23, 24
  - pharmaceuticals evaluation 542
  - social health insurance 130
- New Zealand
  - DCA (direct to consumer advertising) 306
  - hospital competition 221
  - providers, temporary movement of 171
- Newhouse, J.P. 109, 126, 128, 221, 223, 247, 270–71, 283, 338, 339, 340
- Nigeria
  - contracting-out 252
  - public health intervention 55
- NLSY (National Longitudinal Survey of Youth) 67, 68, 75
- NOAA (National Oceanic and Atmospheric Administration) 394
- Norton, Edward C. 266, 296–305
- Norway
  - capitation system 274
  - child mortality 49
  - EuroWill project 398
  - GATS commitments 168
  - helicopter ambulance evaluation 396–7, 398
  - hospital competition 228
  - providers, temporary movement of 172
  - public health expenditure 221
  - social insurance reform 42
- nursing home quality of care 296–305
  - chain ownership 298
  - CON (certificate of need) policies 298, 300, 301, 302
  - demand-side 297–8
  - literature review 300–303
  - market characteristics 297–300, 302
  - Medicaid payments 296, 297, 298, 299, 300–301, 302
  - Medicare payment 296, 297, 298, 299, 301–2
  - occupancy rates 298, 300
  - OSCAR reporting systems 299
  - ownership type 302–3
  - productivity measurement 336, 337, 340
  - publicizing 303
  - quality assurance 299–300
  - service financing 296–7
  - supply-side 298
- nutrition 48–51, 52, 55
  - food fortification 52
  - vitamin A *see* vitamin A
  - see also* diet
- Nyman, John A. 95–103, 104, 107, 117, 128, 299, 300, 301, 451
- Oaxaca-type decomposition 179, 180–81, 182, 183, 184, 187
- obesity 10, 11, 12
  - behavioural theory of weight 76–7, 80
  - consequences of 77–9

- economics of 72–82
- food addiction 76, 77
- health implications 77–8
- labour market effects 78–9
- and Medicaid 78, 79
- neoclassical case for intervention 79–80
- neoclassical theory of weight 74–6, 77
- over-eating 36
- and public policy 79–80
- and snack food 77
- Swedish Obese Subjects (SOS) study 78
- trends in 72–4
- in young people 62, 66
- see also* diet; weight
- O'Brien, B. 365, 372, 394, 397, 430, 498, 504, 527, 534
- obstetrics
  - and performance measurement 332
  - see also* pregnancy
- O'Donnell, Owen 179–92, 193, 209, 211
- OECD
  - health care financing 211
  - macroeconomic effects on mortality 8, 9, 10
  - public health expenditure 221, 222
  - see also* individual countries
- Olmstead Decision, Supreme Court 298
- Olmstead, Todd A. 83–92
- OLS model 439, 441, 442, 444
- Olsen, J.A. 129, 383, 384, 386, 392, 394, 396, 397, 429
- Oman, GATS commitments 168
- ophthalmology 200, 308–9, 373
- organ transplants 132
- OSCAR reporting systems 299
- osteoarthritis 77, 312, 366
- osteoporosis 452
- Pakistan
  - child health and maternal services 209
  - child mortality 51, 58, 207
  - contracting-out 252
  - GATS commitments 168
- Palmer, Natasha 250–58
- Panama, GATS commitments 168
- patient preferences 411
- Pauly, M. 98, 99, 104, 115, 116, 126, 144, 238, 339
- 'pay-for-performance' schemes 266, 267, 276, 288, 289–90
- penicillin 48
- pension plans 26–7
- performance of health care organizations,
  - measuring 317–25
  - adverse selection 321–3, 324
  - agent generated 321–3
  - conjoint analysis 320
  - gaming 322–3, 330
  - joint outputs 324
  - measurement instruments 321–3
  - moral hazard 323–4
  - mortality rates 323
  - parametric frontier methods 320
  - patient satisfaction 321
  - principal-agent model 317–18, 321, 323–4, 326–7
  - principal's objectives 319–20
  - 'ratchet' effect 322–3
  - targets and rewards 321–2
  - waiting times 323
- performance measures in health care systems,
  - use of 319, 326–34
  - behavioural impact 330–31
  - 'best practice' 327
  - evidence on use and impact of 329–32
  - gross outcomes 327–8
  - motivation, intrinsic 326–7
  - net outputs 328
  - not-for-profit organizations 326
  - outcome impact 331–2
- PCPA (physician clinical performance assessment) 329
- process and outcome measures 327–8
- public disclosure 328, 330
- rationale for 327–9
- special features 326–7
- performance-based bonuses, and immunization 290
- personal medical care 46–7
- personal responsibility 384, 385–6
- see also* self-assessed health
- pertussis 57
- Peru, unofficial health care economy 159
- Pharmacare 118, 119, 120
- pharmaceuticals
  - advertising *see* advertising
  - evaluation *see* individual countries
- Philippines
  - child health and maternal services 209
  - child mortality 51, 58, 207
  - health care financing 212
  - poverty and health care expenditure 213
  - providers, temporary movement of 171, 172
  - public health intervention 55, 58
  - vitamin A programme 58
- Philipson, Tomas J. 58, 64, 72–82, 297–8
- physical inactivity 10, 11
- see also* exercise

- physician as patient's agent 261–8, 270, 286  
 agency theory 261–3  
 compensation systems 262–4  
 DCA impact 309  
 economic behaviour 264–7  
 economic theories 261–4  
 implications 267  
 'pay-for-performance' schemes 266, 267, 276, 288, 289–90  
 welfare implications 262
- physicians, productivity measurement 336
- Pinto, Jose Luis 347–58, 385, 388, 405
- pneumonia 7, 54, 58, 452
- Poisson regression model 148, 149, 150, 442, 444
- Poland  
 GATS commitments 168  
 trade in health services 170  
 unofficial health care economy 156
- polio 57
- pollution 11
- Polsky, Daniel 154, 430, 455–65, 504
- pooled data, and location-specific fixed effects 6–11
- Portugal  
 child mortality 49  
 EuroWill project 398  
 Panel Study 23, 24  
 public-private partnerships 239
- poverty  
 and globalization 173  
 and health care expenditure in Asia 212–13, 216  
 and prescription drug insurance 119  
 reduction 51, 88, 173, 251
- preference-based measures for health 371–81  
 data preparation 374–5  
 health state classifications 371–5  
 item generation and selection 372–3  
 ME (magnitude estimation) 373  
 modelling 375–7  
 patient values, use of 374  
 PTO (person trade-off) 373, 386  
 respondents 374  
 SG (standard gamble) 373, 375, 376, 411  
 specificity 372  
 TTO (time trade-off) 373, 411  
 valuation technique 373–4  
 VAS (visual analogue scaling) 373  
*see also* economic evaluation, distributional judgements; quality of life assessment, health-related
- pregnancy  
 Caesarean section rates 290  
 neonatal deaths 8  
 obstetrics, and performance measurement 332  
 unwanted 62
- prescription glasses 308–9
- price elasticity of derived demands 63
- primary care incentives, and capitation system 269–78
- productivity analysis in health care 320, 335–42  
 DEA (Data Envelopment Analysis) 339, 340  
 duality theory 335  
 economies of scale and scope 336, 337  
 efficiency based methods 336–8  
 FDH (Free Disposal Hull) 339–40  
 and financial incentives 338  
 health organizations 337  
 inefficiency measurement 338–40  
 integrated frontier methods 340  
 non-parametric frontier methods 339–40  
 nursing homes 336, 337  
 parametric frontier methods 339  
 patient panel sizes 337–8  
 physicians 337–8  
 process improvement 340  
 RVUs (relative value units) 337  
 technical efficiency 336
- Propper, Carol 227, 238, 248, 292, 317, 319, 324, 326–34, 335
- PSID (US Panel on Income Dynamics) 19
- psychosocial health 199
- public health interventions  
 children in developing countries 46–61  
 community based 52  
 cost-effective 56–8  
 disease control 52–6  
 immunization 53, 54, 55, 57–8  
 margins in 47–8  
 market failures 47  
 and mortality decline 48–51  
 and obesity 79–80  
 personal intervention 53–6  
 technology assessment 56–8  
 vs. individual 46–7
- Punjab, child mortality 51
- QALY (quality-adjusted life-year) model  
 breast cancer 456, 463–4  
 cancer 349  
 cost-effectiveness analysis and clinical trials 509  
 cost-effectiveness analysis, decision rules 471–2, 473–5, 495

- cost-effectiveness analysis, principles and practice 480, 487, 488, 489, 497, 499  
 decision-making 541, 543–4  
 economic evaluation, distributional judgements in 382–90, 393, 394, 397–9  
 health economics, discrete choice experiments in 405, 410, 411  
 health utility measurement 347, 348–50, 351, 353–4, 355–6, 366, 367, 371, 372  
 HIV 470  
   and testicular cancer 349  
 Qatar, GATS commitments 168  
 quality of life assessment, health-related 247, 359–70  
   applications 365–6  
   construct validity 364  
   EuroQol EQ-5D measure 361–2, 364, 365, 366, 372, 373, 377  
   future directions 366–8  
   HUI (Health Utilities Index) 361, 362, 363–4, 365, 366, 372, 373  
   and life expectancy 366–7  
   multi-attribute utility 359–64, 367, 374  
   psychometric measures 359  
   Quality of Well Being scale 361, 362, 363, 364  
   SF-6D scale 361, 362, 364, 365, 371, 373, 377  
   SG (standard gamble) 360, 373  
   Short-Form 36 359, 361, 364, 366, 373  
   TTO (time trade-off) 360  
   VAS (visual analogue scale) 360, 362, 363, 373  
   *see also* economic evaluation, distributional judgements; preference-based measures for health
- Raikou, Maria 247, 429–38, 504  
 RAND Health Insurance Experiment (HIE) 99, 109–10, 131, 151, 286, 440  
 Rannan-Eliya, Ravindra 193, 205–18  
 Rasch analysis 373  
 rational addiction model 62, 64  
 renal disease 289, 364, 452  
 respiratory disorders 52, 77, 200, 209  
 retirement 26, 28, 30, 31, 32, 202, 203  
   early 18, 27, 31  
   *see also* ageing  
 rheumatoid arthritis 114  
 rhinitis 367  
 Rice, Nigel 17–25, 190, 275  
 Rice, Thomas 46, 104, 261–8, 270, 286  
 risk adjustment  
   adverse selection 281–2, 283  
   and ageing 279, 280, 282  
   conventional 279, 282, 283  
   cost-effectiveness analysis 488–9  
   group access 281–2, 284  
   health care evaluation 527–33  
   health insurance 115–16, 126, 127, 142  
   heart disease 392  
   individual access 280–81  
   mental health 292  
   optimal 275–6, 279–85  
   practice of 284–5  
   quality of care 282–4  
   social health insurance 126, 127, 129, 130, 131, 132, 134  
   transport safety 392  
   *see also* health plans  
 risk factors 486  
 Robert Wood Johnson Foundation 289  
 Roberts, Jennifer 258, 348, 360, 371–81, 388, 405  
 Robinson, James 142, 223, 226, 266, 272, 275, 289  
 Romania, trade in health services 170  
 rotavirus 54, 58  
 ‘rotten kids’ model 64  
 Rubin, D. 41, 431, 432, 435, 456, 459  
 Rufen ibuprofen 307  
 Ruhm, Christopher J. 5–16, 67, 68  
 Russia  
   health plan competition 221  
   performance measurement (former Soviet Union) 322  
   smoking 65  
 Rwanda, GATS commitments 168  
 Ryan, Mandy 247, 262, 320, 386, 393, 394, 395, 397, 405–14, 415, 416
- Saint Lucia, GATS commitments 168  
 St. Vincent, GATS commitments 168  
 sanitation 47, 55, 486  
 SARS virus 173  
 Saudi Arabia, health care quality 170  
 Scandinavia  
   hospital choice 223  
   *see also* individual countries  
 schizophrenia 119  
 Schoenbaum, Michael 266, 276, 286–95  
 screening programmes 46, 410, 412  
 Sculpher, Mark J. 410, 429, 480, 488, 498, 504, 514–25, 524, 527, 534, 542  
 selection bias in observational data 455–65  
   addressing 458–63  
   ATE (Average Treatment Effect) 457–8, 460–61, 462, 463

- breast cancer example 455–6, 463–4
- definition 458
- evaluation and selection bias 456–8
- hidden biases 460–62
- matched sampling 460
- model of treatment choice 457
- model-based covariate adjustment 459, 460
- propensity score matching 459–60
- study designs 458–9
- self-assessed health (SAH) 21, 23, 29–30, 31
  - cultural differences 30
  - personal responsibility 384, 385–6
- Senegal
  - contracting-out 252
  - GATS commitments 168
- senior citizens *see* ageing; retirement
- sexual behaviour
  - erectile dysfunction drugs 118
  - sexually transmitted diseases 62, 69, 412
  - and substance abuse 40
  - unsafe 486
  - in young people 67, 68
  - see also* HIV
- Shackley, Phil 247, 392–402, 405
- sibutramine (weight-loss drug) 78
- Sierra Leone, GATS commitments 168
- Sindelar, Jody L. 83–92
- skin complaints 200
- sleep apnoea 77
- sleep patterns 11
- Slovak Republic, GATS commitments 168
- Slovenia, GATS commitments 168
- Smith, Peter C. 223, 292, 317–25, 328, 330, 335, 517
- Smith, Richard 164–75, 237, 392, 394
- smoking 10, 11, 36–7, 41
  - and body weight 66
  - cost-effective analysis 480–86, 488–9
  - early behaviour 42–3
  - and price 65–6
  - and young people 62, 63, 64–5, 66, 67, 68
- snob effects 62–3
- social health insurance
  - administrative costs 130–31, 132
  - competitive 129–30, 132
  - cream-skimming 129–30, 132
  - economics of 126–36
  - efficiency reasons 126–7
  - equity reasons 127–8
  - future challenges 133–4
  - and government re-election 128, 129, 132
  - health redistribution 128–9
  - international purchasing 134
  - loss, non-insurable 131
  - medical care redistribution 128
  - moral hazard 129, 131–2
  - optimal design 130–31
  - public choice reasons 128–9
  - public health insurer 130, 132
  - rationing 132–3
  - risk assessment 126, 127, 129, 130, 131, 132, 134
  - supply of 129–30
  - technology changes 134
  - ‘umbrella’ policies 134
  - wealth redistribution 128
  - welfare gains 127
- social isolation 12
- social security 26–7, 214, 255
- socioeconomic status (SES) 18–19, 20, 21, 22
  - and early life conditions 33
  - and health and health care inequalities 179, 385–6
  - and health and health care inequities *see* equity
  - surveys, limits of 197, 206
- Somanathan, Aparnaa 193, 205–18
- South Africa
  - contracting-out 252, 255, 256, 257
  - GATS commitments 168
  - health services trade 170
  - providers, temporary movement of 171
  - public health intervention 54
- South America
  - cost-effective analysis on alcohol and tobacco use 480–86, 488–9
  - see also* individual countries
- South Korea
  - health care financing 212
  - health care utilization 208
- Southeast Asia
  - public health intervention 54
  - see also* individual countries
- Spain
  - hospital competition 221
  - macroeconomic effects on mortality 9
  - Panel Study 23, 24
  - smoking 65
- Sri Lanka
  - child mortality 51, 58, 207
  - equity in health care 205
  - FDI 170
  - government social spending 209, 211
  - health care financing 212, 214
  - health care utilization 208
  - health inequalities 206
  - poverty and health care expenditure 212, 213
  - tax systems, predominant 214–15



- state dependence 20–21, 27  
 Stinnett, A. 499, 504, 515, 528, 534  
 Street, Andrew 223, 292, 317–25, 330, 331, 335  
 Street, Deborah J. 386, 415–26  
 streptomycin 48  
 stress 11  
 strokes 77, 364, 366  
   and physician experience on the treatment of 339  
 substance use *see* drug use  
 suicide  
   and economic instability 5, 7, 8  
   and young people 62, 67  
 supplier-induced demand 39–40  
 Sutton, Matt 181, 193–204, 373–4  
 Swaziland, GATS commitments 168  
 Sweden  
   GATS commitments 168  
   health care use 149  
   hospital competition 221, 228  
   inequalities in self-reported health 181  
   (PES) Public Employment System data 29  
   prescribing behaviour 309  
   providers, temporary movement of 171  
   public health expenditure 221  
   Swedish Obese Subjects (SOS) study 78  
   unemployment 29  
 Switzerland  
   alcohol and price 65  
   child mortality 49  
   GATS commitments 168  
   health insurance 112  
   health plans 221, 285  
   hospital competition 228  
   performance measurement 332  
   public health expenditure 221  
   social health insurance 130  
 Taiwan  
   cross-border supply of services 167  
   health care financing 211, 212, 214  
   health care use 207  
   health care utilization 208  
   poverty and health care expenditure 213  
   social security systems 214  
 Tan-Torres Edejer, Tessa 479–91  
 Tanzania  
   health care workers 53  
   public health intervention 55  
 technology changes 134  
 technophysio-evolution 48, 51  
 testicular cancer, and QALY model 349  
 tetanus 57  
 Thailand  
   government social spending 209  
   health care financing 212, 214  
   health care utilization 208  
   health services trade 170  
   poverty and health care expenditure 213  
   tax systems, predominant 214–15  
 Thompson, Robin 156–63, 215  
 thyroid problems 120  
 time preference rates 18  
 time series analysis 5–6  
 Torrance, G.W. 360, 361, 362, 373, 375  
 tourism 170, 173  
   *see also* migration  
 traffic deaths 7, 8, 9  
   and alcohol 10  
   and young people 62, 68  
 traffic safety, risk reduction 392  
 transition countries  
   hospital stays, length of 161  
   unofficial health care economy 156, 157, 161  
   *see also* individual countries  
 Trinidad and Tobago, GATS commitments 168  
 Trivedi, Pravin K. 147–55  
 Tsuchiya, Aki 129, 382–91, 541  
 tuberculosis 52, 57, 251, 486  
 Turkey, GATS commitments 168  
 typhoid 52, 54  
 Uganda  
   contracting-out 252, 256  
   health care workers 53  
   unofficial health care economy 156  
 UK 23, 24, 31  
   bargaining in health care 237, 238  
   BHPS (British Household Panel Survey) 19, 20, 21, 23  
   child mortality 49  
   contracting-out 250, 253  
   cost effective analysis 495, 499, 537–9  
   day case treatment 199–202  
   distributional judgements 385  
   District Health Authorities 227  
   drug-related crime 83  
   equity in health care consumption in England 199–203  
   ethnicity 199–203  
   EuroWill project 398  
   financial incentives 289, 292  
   fixed price contracts 246  
   GP consultations 199–202, 203  
   GP (general practitioner) fundholding 117–18, 119, 227, 238, 271, 274

- health resource group (HRG) 246, 248
- health services trade 170
- hospital competition (England) 221, 223, 226–7, 228
- hospital waiting times 238
- in-patient stays 199–202
- inequalities in self-reported health 181
- London Patient Choice Project (LPCP) 227
- National Health Service 126, 238, 246, 289, 499
- National Health Service Act 95
- NHS Health Technology Assessment Programme 384
- NHS 'internal market' 226–7
- NICE (National Institute for Health and Clinical Excellence) 397, 410–11, 495, 499, 500, 514, 516, 524, 537–8, 540, 542, 543–4
- out-patient visits 199–202, 203
- performance measurement 326, 330, 331
- pharmaceuticals evaluation 537–8, 540, 542, 543–4
- PPS (prospective payment system) 246
- prescribing cost reduction 227
- Primary Care Trusts 272, 274
- providers, temporary movement of 171, 172
- public health expenditure 221
- public-private partnerships 239
- quality assessment 361
- quality incentive programme 289
- smoking 65
- technology assessment 514, 516, 524
- transport safety policy 399
- willingness to pay 399
- ulcers, and advertising 310
- UN Millennium Development Goals (MDGs) 251
- unemployment 6, 7, 8, 9, 10, 18
  - Germany 32
  - insurance 31
  - Sweden 29, 30
- Uruguay, child mortality 50
- USA
  - 'any willing provider' laws 235
  - bargaining in health care 237
  - BBA (Balanced Budget Act) 297
  - Boren Amendment 297
  - calorie consumption 73–4
  - Canada, importing drugs from 114, 121
  - capitation payments 265–6, 271–2
  - child mortality 50
  - child mortality decline 48
  - DCA (direct to consumer advertising) 306–8, 309–10, 311–12
  - diagnosis related group (DRG) 246, 248
  - Drug Policy Alliance 83
  - drug smuggling 88
  - drug subsidies to seniors 115
  - drug use 83, 84, 87
  - drug-related crime 83, 85
  - financial incentives 288–9
  - fixed price contracts 246
  - GATS commitments 167, 168
  - health insurance 32, 99, 102, 147
  - health maintenance organizations (HMOs) 117, 118, 119, 120, 233, 237, 238, 264, 266, 271, 527
  - health plans 138, 142, 143, 144, 147, 221, 271, 281–2, 284, 287, 288, 326
  - and health services trade 170
  - HEDIS (Health Plan Employer Data Information Set) 326, 331, 332
  - height of men 48, 51
  - hospital competition 223, 224, 226
  - income levels 11
  - Leapfrog Group for Patient Safety 288
  - legal drinking age 84
  - life expectancy 453
  - macroeconomic effects on mortality 6–8, 9, 10, 11
  - managed care industry 144
  - marijuana use 83
  - Medicaid *see* Medicaid
  - medical costs 450
  - Medicare *see* Medicare
  - MEPS-IC (Medical Expenditure Panel Survey – Insurance Component) 145
  - mortality rates 330
  - National Health Interview Survey 72
  - NSDUH (National Survey on Drug Use and Health) 84
  - nursing home care 296–305, 340
  - obesity 72–3, 78, 79
  - OBRA87 (Omnibus Budget Reconciliation Act) 299
  - Olmstead Decision, Supreme Court 298
  - 'orphan drug' treatments 527
  - OSCAR reporting system 299
  - outpatient visits 149
  - 'pay-for-performance' schemes 267
  - payment rate freezes 265
  - performance measurement 324, 326, 330, 331–2
  - PPS (prospective payment system) 246, 297, 301–2
  - prescribing behaviour 309–10
  - prescription drugs 83, 84
  - providers, temporary movement of 172
  - PSID (Panel on Income Dynamics) 19

- public health expenditure 221  
 RAND Health Insurance Experiment (HIE)  
 99, 109–10, 131, 151, 286, 440  
 retirement 27  
 Robert Wood Johnson Foundation 289  
 self-reported disability 30  
 smoking 65, 66  
 Social Security Act Amendments 97–8  
 surgical success rates 324  
 USAID 256  
 value-based purchasing 288  
 water quality 52
- vaccination 52, 53, 54, 57–8, 452  
 and performance measurement 332  
*see also* immunization
- van Doorslaer, Eddy 22, 23, 179–92, 193, 194,  
 207, 208, 212, 213
- Vanness, David J. 514, 526–36
- vector control 55, 57
- Venezuela, unofficial health care economy 159
- Vietnam  
 child health and maternal services 209  
 child malnutrition 180–81  
 child mortality 51, 58, 186, 207  
 head-for-age z-scores for children (HAZ)  
 181, 182, 185, 186, 187, 188–90  
 health care use 150  
 health financing 215  
 health inequalities 185–6  
 poverty and health care expenditure 212, 213  
 transition economies 215
- Viney, Rosalie 386, 405, 415–26
- vitamin A  
 in cereals 52  
 supplementation 48, 55, 57, 58
- Wagstaff, Adam 5, 21, 23, 129, 179–92, 193,  
 194, 207, 208, 212, 213, 251
- waiting lists, and globalization 173
- waiting times 225, 227, 238, 323
- water quality 47, 52, 55, 486
- weight  
 and appearance 79  
 behavioural theory of 76–7, 80  
 BMI (body mass index) 66, 72–3, 75, 78  
 capital investment model of 74  
 and food prices 75–6, 77  
 and income 75  
 loss 78  
 neoclassical theory of 74–6  
 sibutramine (weight-loss drug) 78  
 and smoking 66  
 and technology 75  
*see also* diet; obesity
- Weinstein, Milton C. 447, 469–78, 493, 494,  
 495, 505, 508
- WHO (World Health Organization) 53, 55, 57,  
 129, 206, 320  
 CHOICE (Choosing Interventions that are  
 Cost-Effective) project 486  
 health definition 371–2  
 Health InterNetwork 167  
 International Classification of Impairment,  
 Disabilities and Handicaps 372  
 league tables 324  
 Williams, A. 24, 194, 196, 198, 320, 384, 492,  
 493, 497, 500, 541  
 willingness to pay (WTP) 392–9, 403, 406, 410
- Wilson, Deborah 248, 292, 319, 324, 326–34,  
 335
- workforce  
 inexperienced 11  
 older 26–35  
*see also* employment
- World Bank Health Sector Priorities Review  
 486
- World Health Organization *see* WHO
- WTO (World Trade Organization) 165
- WTP (willingness to pay) 392–9, 403, 406, 410
- Yellow Fever 55
- young people  
 alcohol use 62, 64, 65, 66, 67, 68–9  
 death, leading causes of 62  
 health behaviours among 62–71  
 maternal employment, effects of 67–8  
 NLSY (National Longitudinal Survey of  
 Youth) 67, 68, 75  
 obesity 62, 66  
 peer and parental pressure 62–4, 66–8  
 price pressure 62–6  
 ‘rotten kids’ model 64  
 and sexual behaviour 67, 68  
 and smoking 62, 63, 64–5, 66, 67, 68  
 and suicide 62, 67  
 and traffic deaths 62, 68
- Zambia  
 GATS commitments 167, 168  
 hospital competition 228  
 public health intervention 55
- Zero Tolerance laws 68–9
- Zweifel, Peter 126–36, 149

